Milestone Alert: First Patient Dosed in Phase 3 Study of YCANTH for Common Warts

The first patient was dosed in Verrica Pharmaceuticals Inc.’s global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts.

The first patient was dosed in Verrica Pharmaceuticals Inc.’s global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts.